Biochemical characteristics and clinical manifestation of normocalcemic primary hyperparathyroidism.

Background: Normocalcemic primary hyperparathyroidism (nPHPT) is a condition characterized by persistently high levels of parathyroid hormone (PTH) and normal serum calcium levels in the absence of other causes for secondary hyperparathyroidism. The aim of the present study was to assess the clinical presentation and the biochemical characteristics in patients with nPHPT and to compare them with those in patients with hypercalcemic PHPT (hPHPT).

Materials And Methods: The study included 316 patients (277 women and 39 men, average age 58.

Evaluation of disease-specific quality of life and its influencing factors in Bulgarian patients with Graves' orbitopathy.

Purpose: Graves' orbitopathy (GO) profoundly affects patients' quality of life (QoL). Our aim was to assess QoL in patients with different forms of GO and to search for predictors of QoL.

Methods: This was a cross-sectional study involving 221 consecutive unselected GO patients (77.

CO-EXISTING HASHIMOTO'S THYROIDITIS DOES NOT AFFECT BONE METABOLISM IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM.

Context: Primary hyperparathyroidism (PHPT) is often associated with thyroid disorders like nodular goiter, Hashimoto's thyroiditis (HT) and Graves' disease.

Objective: Our aim was to explore whether the co-existence with HT affects bone metabolism in patients with PHPT.

Design: This was a comparative cross-sectional study carried out in a tertiary inpatient endocrine center from January 2018 through December 2020.

Comparison of the efficacy of two different glucocorticoid regimens for treatment of active moderate-to-severe Graves' orbitopathy.

Purpose: Intravenous glucocorticoids (GCs) are the mainstay of treatment for severe forms of Graves' orbitopathy (GO). Our aim was to assess the effectiveness and safety of a modified monthly regimen (mMR) and to compare them with those of the established weekly regimen (WR).

Methods: This was a prospective non-randomized single-center study involving 62 patients, divided into two therapeutic groups depending on their referral time.

Changes in therapeutic response, ocular manifestations of Graves' orbitopathy and quality of life during the first year after orbital radiotherapy.

Purpose: The aim of our study was to assess the changes in the therapeutic response, ocular manifestations of GO and quality of life during the first year after OR.

Methods: The study involved 26 consecutive patients with active moderate-to-severe GO indicated for OR, 18 females, mean age 57 ± 12.5.